Cordycepin (3′-deoxyadenosine) down-regulates the proinflammatory cytokines in inflammation-induced osteoporosis model

Inflammation

Volumn 37, Issue 4, 2014, Pages 1044-1049

  Zhang, Da Wei ^a   Wang, Zhen Lin ^c   Qi, Wei ^a,b   Lei, Wei ^a   Zhao, Guang Yue ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b 520th Hospital of PLA   (China)

^c No 113 Hospital of People's Liberation Army   (China)

Author keywords

bone marrow cell; cordycepin; IMO; proinflammatory cytokines

Indexed keywords

ALDEHYDE; COLLAGEN TYPE 1; CORDYCEPIN; CYTOKINE; DEOXYADENOSINE DERIVATIVE; INTERLEUKIN 1BETA; MALEALDEHYDE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; INFLAMMATION; LIVER; METABOLISM; NEUTROPHIL; OSTEOPOROSIS; PATHOLOGY; RAT;

ALDEHYDES; ANIMALS; COLLAGEN TYPE I; CYTOKINES; DEOXYADENOSINES; DOWN-REGULATION; INFLAMMATION; INTERLEUKIN-1BETA; LIVER; NEUTROPHILS; NITRIC OXIDE; OSTEOPOROSIS; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904753439     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9827-z     Document Type: Article

References (30)

1. Yun, A.J., and P.Y. Lee. 2004. Maldaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis. Medical Hypotheses 63: 532-537.
2. Mitra, D., D.M. Elvins, D.J. Speden, and A.J. Collins. 2000. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology (Oxford) 39(1): 85-89. (Pubitemid 30095412)
3. Moschen, A.R., A. Kaser, B. Enrich, et al. 2005. The RANKL/OPG system is activated in inflammatory bowel diseases and relates to the state or bone loss. Gut 54: 479-487. (Pubitemid 40395499)
4. Saidenberg-Kermanach, N., M. Cohen-Solal, N. Bessis, M.C. De Vernejoul, and M.C. Boissier. 2004. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 71: 9-13. (Pubitemid 38183280)
5. Lorenzo, J. 2000. Interactions between immune and bone cells: new insights with many remaining questions. Journal of Clinical Investigation 106: 749-752.
6. Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
7. Kim, H., A.S. Naura, Y. Errami, J. Ju, and A.H. Boulares. 2011. Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP. Molecular Medicine 17: 893-900.
8. Kim, H.G., B. Shrestha, S.Y. Lim, D.H. Yoon, W.C. Chang, D.J. Shin, et al. 2006. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NFkappaB through Akt and p38 inhibition in RAW 264.7 macrophage cells. European Journal of Pharmacology 545: 192-199.
9. Noh, E.M., J.S. Kim, H. Hur, B.H. Park, E.K. Song, M.K. Han, et al. 2009. Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford) 48: 45-48.
10. Ni, H., X.H. Zhou, H.H. Li, and W.F. Huang. 2009. Column chromatographic extraction and preparation of cordycepin from cordyceps militaris waster medium. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 877: 2135-2141.
11. Minne, H.W., J. Pfeilschifter, S. Scharla, S. Mutschelknauss, A. Schwarz, B. Krempien, and R. Ziegler. 1984. Inflammation-mediated osteopenia in the rat: a newanimalmodel for pathological loss of bone mass. Endocrinology 115: 50-54. (Pubitemid 14086788)
12. Grabowski, P.S., A.J. England, R. Dykhuizen, M. Copland, N. Benjamin, D.M. Reid, and S.H. Ralston. 1996. Elevated nitric oxide production in rheumatoid arthritis: detection using the fasting urinary nitrate:creatinine ratio. Arthritis and Rheumatism 39: 643-647.
13. Ohshima, H., I.M. Brouet, T. Bandaletova, H. Adachi, S. Oguchi, S. Iida, Y. Kurashima, Y. Morishita, T. Sugimura, and H. Esumi. 1992. Polyclonal antibody against an inducible form of nitric oxide synthase purified fromthe liver of rats treatedwith propionibacteriumacnes and lipopolysaccharide. Biochemical and Biophysical Research Communications 187: 1291-1297.
14. Deodhar, A.A., and A.D. Woolf. 1996. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. British Journal of Rheumatology 35: 309-322.
15. Andreassen, H., J. Rungby, J.F. Dahlerup, and L. Mosekilde. 1997. Inflammatory bowel disease and osteoporosis. Scandinavian Journal of Gastroenterology 32: 1247-1255. (Pubitemid 28023130)
16. Minne, H.W., J. Pfeilschifter, S. Scharla, et al. 1984. Inflammation-mediated osteopenia in the rat: a new animal model for pathological loss of bone mass. Endocrinology 115: 50-54. (Pubitemid 14086788)
17. Minne, H.W., J. Pfeilschifter, S. Scharla, S. Mutschelknauss, A. Schwarz, B. Krempien, and R. Ziegler. 1984. Inflammation-mediated osteopenia in the rat: a new animal model for pathological loss of bone mass. Endocrinology 115: 50-54. (Pubitemid 14086788)
18. Pfeilschifter, J., C. Wuster, M. Vogel, B. Enderes, R. Ziegler, and H.W. Minne. 1987. Inflammation-mediated osteopenia (IMO) during acute inflammation in rats is due to a transient inhibition of bone formation. Calcified Tissue International 41: 321-325.
19. Polak-Jonkisz, D., and D. Zwolinska. 1998. Osteocalcin as a biochemical marker of bone turnover. Nephrology 4: 339-346. (Pubitemid 29090767)
20. Koh, J.M., Y.S. Lee, Y.S. Kim, et al. 2006. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. Journal of Bone and Mineral Research 21: 1003-1011. (Pubitemid 43962829)
21. Herrmann, M., N. Umanskaya, B. Wildemann, et al. 2008. Stimulation of osteoblast activity by homocysteine. Journal of Cellular and Molecular Medicine 12: 1205-1210.
22. Burgeson, R.E. 1988. New collagens, new concepts. Annual Review of Cell Biology 4: 552-577.
23. Guerrero, R., M.A. Diaz Martin, E.M. Diaz Diego, et al. 1996. New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis. Osteoporosis International 6: 297-302. (Pubitemid 26280823)
24. Sánchez-Rodríguez, M.A., M. Ruiz-Ramos, E. Correa-Muñoz, and V.M. Mendoza-Núñez. 2007. Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskeletal Disorders 8: 124.
25. Widomski, D., D.J. Fretland, A.F. Gasiecki, and P.W. Collins. 1997. The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. Immunopharmacology and Immunotoxicology 19: 165-174. (Pubitemid 27192329)
26. Zoppo, G.J., G.W. Schmid-Schonbein, E. Mori, B.R. Copeland, and C.M. Chang. 1991. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 22: 1276-1283.
27. Hartl, R., L. Schurer, G.W. Schmid-Schonbein, and G.J. Zoppo. 1996. Experimental antileukocyte interventions in cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 16: 1108-1119. (Pubitemid 26365361)
28. Pacifici, R. 1996. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. Journal of Bone and Mineral Research 11: 1043-1051. (Pubitemid 26321353)
29. Poli, V., R. Balena, E. Fattori, A. Markatos, M. Yamamoto, H. Tanaka, et al. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO Journal 13: 1189-1196. (Pubitemid 24074725)
30. Ralston, S.H., L.P. Ho, M.H. Helfrich, P.S. Grabowski, P.W. Johnston, and N. Benjamin. 1995. Nitric oxide: a cytokine-induced regulator of bone resorption. Journal of Bone and Mineral Research 10: 1040-1049.